As always, consider your individual needs and speak with a healthcare professional before starting a new supplement.
ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag
IV Therapy is much more effective at getting your body the vitamins and minerals you need
At a cellular level, GHK-Cu activates dermal fibroblasts and essential growth-signaling pathways
GST catalyzes the conjugation of reduced glutathione to electrophilic xenobiotics and utilizes reduced glutathione to scavenge potentially toxic compounds
The key difference is that retatrutide provides triple agonism (GLP-1 + GIP + glucagon) while semaglutide provides only GLP-1 agonism